Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Click chemistry breakthroughs drive Shasqi and J&J cancer alliance

By Brian Buntz | October 11, 2023

ShasqiIn June 2023, the click chemistry-focused startup Shasqi revealed a research pact with Johnson & Johnson Enterprise Innovation. More recently, the company announced that it had expanded the research alliance, furthering work on its intratumorally injected biopolymer, known as SQL70. The collaboration will also apply its clinically validated Click Activated Protodrugs Against Cancer (CAPAC) technology to the development of new cancer therapies through preclinical testing.

Inside the click chemistry Shasqi J&J alliance

Shasqi is working with an interventional oncology unit at J&J, which is aiming to take a holistic approach to cancer care that spans therapeutics and therapeutic approaches to meet unmet needs. “That completely matches with our view of the world,” said Dr. José M. Mejía Oneto, the founder and CEO of Shasqi.

The partnership with J&J will bolster research on Shasqi’s intratumorally injected biopolymer SQL70 but also support the development of an additional payload through preclinical testing.

“We’re now expanding beyond just biopolymers,” Oneto said. “We’re focusing on antigen targeting activators that can be infused into the body, which will bind to specific receptors and harness the power of click chemistry.”

The expanded collaboration with J&J is evidence of the growing traction of click chemistry. In 2022, click chemistry pioneers Carolyn R. Bertozzi, Morten Meldal, and K. Barry Sharpless won the Nobel Prize of Chemistry for their work in click chemistry and bioorthogonal chemistry.

Before that milestone, Oneto recalls having to “explain to people what click chemistry is.” But afterwards, people grasped its import. The partnership with J&J focused on click chemistry is further evidence of its evolving status.

Toward precision activation in cancer treatment

On Shasqi’s website, the company notes that a small percentage of drugs make it to their desired location in the body. “Imagine a world where cancer drugs are activated only where they are needed,” it reads. Oneto elaborated on this vision, stating, “Our goal is to create a world where drugs are activated exactly where you want them.” Drug developers may not be able to control how therapies get distributed, but “can you control where the activation of the powerful therapy that you want to give happens?” Oneto asked. “And so from our perspective, there’s multiple ways to enable that to happen. One is through a direct injection into a location in your body and the other one is through known receptors in a tumor.” Ultimately, the ability to selectively control where the activation occurs is “critical,” Oneto concluded, as it sets the stage for new possibilities in targeted cancer treatment.

A recent publication in ACS Central Science underscores the potential of Shasqi’s approach. The paper describes how Shasqi’s CAPAC platform used a click chemistry reaction between tetrazine and trans-cyclooctene to activate cancer drugs at specific tumor sites. This approach allowed for targeted activation either through intratumoral injection of a tetrazine-modified hyaluronate or by infusion of a tetrazine-modified HER2-targeting antigen-binding fragment. The study highlighted the efficacy of SQP22, a novel protodrug activated through click chemistry.

“That separation of the payload from targeting gives you an enormous amount of flexibility in terms of how you saturate those receptors,” Oneto said, referring to tumor-associated receptors such as HER2. Instead of the traditional approach where two agents are firmly tethered together, as in an antibody drug conjugate (ADC), the CAPAC platform uses click chemistry to activate drugs at specific tumor sites. By either intratumorally injecting a tetrazine-modified hyaluronate or infusing a tetrazine-modified HER2-targeting antigen-binding fragment, the method allows for receptors to first be targeted with a harmless agent that doesn’t carry the therapeutic component. “You can then follow up with the required payload dose. This enables activation where you want it.”


Filed Under: clinical trials, Drug Delivery, Drug Discovery, Immunology, Oncology
Tagged With: Biopolymer Research, CAPAC Platform, click chemistry, Drug delivery, Johnson & Johnson, Oncology Innovations, Shasqi
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

A display of DNA sequencing output from an automated ABI 373 sequencer. [National Human Genome Research Institute (NHGRI)]
Helix and Recursion join forces in quest to crack the AI-driven drug discovery code
Ypsomed Ypsodose patch injector
ten23 health to develop large-volume injectables for Ypsomed’s YpsoDose
Shasqi
Nobel-connected startup Shasqi deepens J&J partnership on CAPAC platform
ADC image
Exploring future cancer therapies: Designing linkers to increase ADC efficacy and reduce toxicity
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE